Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Common Equity (2016 - 2025)

Bioceres Crop Solutions' Common Equity history spans 9 years, with the latest figure at $295.2 million for Q2 2025.

  • For Q2 2025, Common Equity fell 6.29% year-over-year to $295.2 million; the TTM value through Jun 2025 reached $295.2 million, down 6.29%, while the annual FY2025 figure was $295.2 million, 6.29% down from the prior year.
  • Common Equity for Q2 2025 was $295.2 million at Bioceres Crop Solutions, down from $315.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $330.5 million in Q2 2023 and bottomed at -$357.4 million in Q4 2021.
  • The 5-year median for Common Equity is $226.8 million (2022), against an average of $138.7 million.
  • The largest annual shift saw Common Equity skyrocketed 108.78% in 2023 before it dropped 6.29% in 2025.
  • A 5-year view of Common Equity shows it stood at -$357.4 million in 2021, then skyrocketed by 144.3% to $158.3 million in 2022, then surged by 108.78% to $330.5 million in 2023, then dropped by 4.68% to $315.0 million in 2024, then decreased by 6.29% to $295.2 million in 2025.
  • Per Business Quant, the three most recent readings for BIOX's Common Equity are $295.2 million (Q2 2025), $315.0 million (Q2 2024), and $330.5 million (Q2 2023).